Evidence for the use of ALLEVYN LIFE dressings as part of a pressure ulcer prevention protocol is growing, see some recent publications below.
Positive patient outcomes: The use of a new silicone adhesive hydrocellular foam dressing for pressure ulcer prevention and treatment5
Beth Clarke, RN, Msc(A), MBA, CWOCN
Pressure ulcers are a significant issue for patients across all care settings globally and most hospital acquired pressure ulcers are preventable when effective risk assessment is matched with appropriate interventions. This study outlines the results at Bridgepoint Active Healthcare hospital in Toronto, following the implementation of ALLEVYN Life as an addition to its existing pressure ulcer prevention protocol within the neurological care unit and for wound management in the medical activation unit.
Preventing Sacral Pressure Ulcer Development in the Surgical Patient Population4
Timothy A. Brendle, MS, RN, CNOR, NE-BC
It is estimated that 23% of hospital acquired pressure ulcers are the result of the patient undergoing a surgical procedure. This study outlines the results at Ashley River Tower where a silicone hydrocellular foam sacral dressing was implemented within the perioperative area as part of an overall pressure ulcer prevention program.
Use of a comprehensive pressure ulcer prevention program to reduce the incidence of hospital-acquired pressure ulcers in an intensive care unit setting – summary6
Katie Swafford, MSN, RN, CNS-BC, CCRN, Rachel Culpepper, RN, BSN, CCRN, Christina Dunn, RN, BSN.
Hospital Acquired Pressure Ulcers (HAPUs) are costly and preventable complications. The study from Eskenazi Health shows the results when an acute care ICU implemented a pressure ulcer prevention protocol consistent with international guidelines and in addition implemented ALLEVYN LIFE dressings to be placed on heel and sacral locations. The goal was to reduce incidence of pressure ulcers by 50% compared to the period prior to implementation.
Evaluation of a new silicone gel-adhesive hydrocellular foam dressing as part of a pressure ulcer prevention plan for ICU patients7
Charlotte Lisco, BSN, RN, CWON
The use of foam dressings as part of a pressure ulcer prevention protocol is gaining traction in the US. The aim of this study was to evaluate a new silicone-adhesive hydrocellular foam dressing (ALLEVYN LIFE) as part of a comprehensive pressure ulcer prevention plan to reduce sacral/coccyx pressure ulcers in a 24 bed ICU.
1 National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers: Clinical Practice Guideline. Emily Haesler (Ed.) Cambridge Media: Osborne Park, Western Australia; 2014.
2 Brendle T. Preventing sacral pressure ulcer development in the surgical patient population. Poster presented at OR manager Conference 2015.
3 Clarke B. Positive patient outcomes: The use of a new silicone adhesive hydrocellular foam dressing for pressure ulcer prevention and treatment. Poster presented at CAET 2013.
4 Swafford K, Culpepper R and Dunn C. Use of a comprehensive pressure ulcer prevention program to reduce the incidence of hospital-acquired pressure ulcers in an intensive care unit setting. E-Poster presented at EWMA 2015.
5 Lisco C. Evaluation of a new silicone gel-adhesive hydrocellular foam dressing as part of a pressure ulcer prevention plan for ICU patients. Poster presented at 2013 WOCN Society Conference.
6 Santamaria, N. et al., The cost-benefit of using soft silicone multilayered foam dressings to prevent sacral and heel pressure ulcers in trauma and critically ill patients. International Wound Journal, 2013.
7 Vanderwee, K., et al. Pressure ulcer prevalence in Europe: a pilot study. Journal of Evaluation in Clinical Practice, 13: 227–235. 2007
8 Data on File Report DS/12/125/DOF, June 2012. Roberts S. Impact protection properties of ALLEVYN LIFE, MepilexTM Border and BiatainTM Silicone.
9 OR DOF 020 Performance of silicone dressings – ALLEVYN LIFE and Mepilex Border.
10 Rossington A et al., Clinical performance and positive impact on patient wellbeing of ALLEVYN LIFE. Wound UK. 9(4): 91-95. 2013
11 Data on file report DS/12/123/DOF, June 2012. Roberts S. Physical properties of ALLEVYN LIFE.
All Trademarks acknowledged